Alternatives to Animal Testing Software in 2026

The OECD QSAR Toolbox helps researchers predict properties and hazards of a chemical from its structure and from data on similar chemicals. It supports grouping, read-across and trend analysis, which means a team can estimate an endpoint for an untested chemical by comparing it with tested neighbours. That approach is used in regulatory and industry work to prioritise testing and reduce unnecessary studies.

The tool is free, but it is not a push-button answer machine. Users need to understand chemical categories, data quality and the limits of each model. A prediction without a clear rationale and supporting data will not carry weight in a regulatory discussion. Used well, it is a strong first screen before any lab work begins.

Derek Nexus, from Lhasa Limited, predicts toxicity using expert written rules that link chemical structures to known hazards. When it flags a compound, it shows the reasoning and supporting examples, so a toxicologist can judge whether the alert applies to their specific chemical and use case. That transparency matters, because a bare yes or no is rarely enough for a safety decision.

Derek Nexus is a commercial product with licence pricing, so teams should request a quote based on users and modules. It works best as part of a weight of evidence approach, alongside other prediction tools and lab data. A single alert should prompt review and, where needed, targeted follow-up testing, not an automatic ban or approval.

Emulate builds organ chips that place living human cells on a microfluidic device, with flow and mechanical forces that mimic conditions inside the body. Its Human Emulation System includes instruments, chips and software, and models cover organs such as liver, lung, kidney, brain and intestine. Research using its liver chip has been cited for flagging drugs that passed animal tests but later proved toxic to human livers.

The strength of the system is also its limit. Organ chips are complex, lower throughput than cell plates, and require trained staff and careful quality control. Pricing is project based, so teams should discuss study design and throughput before committing. For a focused human toxicity question, that depth can justify the cost.

CN Bio makes the PhysioMimix system, a microphysiological platform that can link several organ models together so researchers can study how a drug moves and changes across organs. Its liver and gut models are used for drug metabolism, toxicity and disease modelling, and multi-organ work helps answer questions that a single tissue model cannot.

Like other chip platforms, CN Bio suits teams with lab capacity and a clear study design. It is not a screening tool for thousands of compounds at once. Teams should confirm model availability, cell sources and data outputs for their endpoint, and plan for validation work alongside any new model.

MIMETAS offers the OrganoPlate platform, which grows 3D human tissues in a plate format with controlled perfusion. Because the format aligns with standard lab equipment, it is easier to scale than some chip systems, and it is used for drug screening, toxicity assessment and disease modelling. Its blood-brain barrier model is a noted example for neurological drug work.

The platform still demands good cell culture practice and assay design. Results depend on cell source, culture conditions and readouts, so standardisation matters. For teams that want chip-like biology with higher throughput than a single chip instrument, MIMETAS is a practical middle path.

InSphero builds scaffold-free 3D microtissues from human cells, which better reflect tissue architecture than flat cell layers. Its liver microtissues are used for drug induced liver injury work, and its pancreatic islet models support metabolic disease research. The Akura Flow system adds microfluidic perfusion to keep tissues under more lifelike conditions.

The trade with any 3D model is variability. Teams need replicates, controls and clear acceptance criteria, especially when comparing batches or donors. InSphero works best when the research question is specific, such as liver toxicity or islet function, rather than a general screen of unrelated endpoints.

MatTek provides lab grown human tissue models, including EpiDerm for skin. EpiDerm is used for skin irritation, corrosion and related testing, and it has a long history in validation work for non-animal methods. Ready to use tissues let labs run standard assays without building a tissue model from scratch.

The limit is scope. A skin model answers skin questions well and says little about liver, heart or whole body effects. Teams should match the model to the endpoint and check current regulatory acceptance for that use. For cosmetics and chemicals work where skin endpoints matter, MatTek is a direct and practical alternative.

EPA ToxCast is a US Environmental Protection Agency programme that screens chemicals with high throughput assays and publishes the results in a public dashboard. Researchers can look up a chemical, see assay activity across many biological targets, and prioritise chemicals for deeper work. It is a valuable starting point when a team needs to rank a list before spending on lab studies.

ToxCast data alone does not prove safety or harm. Assay hits need context on dose, exposure and relevance to human biology, and many screening results require follow-up. Used as a prioritisation and hypothesis tool, however, it is free, open and widely cited, which makes it a sensible first step in a non-animal workflow.